CT83 and breast cancer: In 2018, Masahiko Watanabe's team analyzed the surgical specimens of 51 patients with breast cancer and found that KK-LC-1 could be detected in triple-negative breast cancer cases and all tumors without estrogen receptor expression, and its expression level in tumor tissues was significantly higher than that in paracancerous tissues.